Following surgery, medianfollow-up was 15 months with a median survival time of 20.6 months.Conclusion: This case series may contribute to the literature on thepathological and clinical aspects of the mixed adenoneuroendocrinecarcinoma of the gastrointestinal system.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aims: Mixed adeno-neuroendocrine carcinoma is a rare entity,diagnosed with immunohistochemical studies.
📊
Key Findings & Data:In our study, weaimed to report a case series from a tertiary hospital with demographicsof the patients, detailed tumor and clinical findings and follow-up plussurvival conditions.Methods: Pathology database was explored for patients with thepathological diagnosis of ‘mixed adeno-neuroendocrine carcinoma’and patients were identified retrospectively and evaluated in meansof demographics, histopathological examination, tumor properties.Results: Ten patients had been diagnosed with mixed adenoneuroendocrinecarcinoma in our center, diagnosed at a mean age of64.7.
💡
Conclusion & Impact:Following surgery, medianfollow-up was 15 months with a median survival time of 20.6 months.Conclusion: This case series may contribute to the literature on thepathological and clinical aspects of the mixed adenoneuroendocrinecarcinoma of the gastrointestinal system.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Aims: Mixed adeno-neuroendocrine carcinoma is a rare entity,diagnosed with immunohistochemical studies. Literature mainlyincludes case reports and series which are very few. In our study, weaimed to report a case series from a tertiary hospital with demographicsof the patients, detailed tumor and clinical findings and follow-up plussurvival conditions.Methods: Pathology database was explored for patients with thepathological diagnosis of ‘mixed adeno-neuroendocrine carcinoma’and patients were identified retrospectively and evaluated in meansof demographics, histopathological examination, tumor properties.Results: Ten patients had been diagnosed with mixed adenoneuroendocrinecarcinoma in our center, diagnosed at a mean age of64.7. Stomach was found to be the most common localization. Fivepatients (50%) were diagnosed as grade 3. Following surgery, medianfollow-up was 15 months with a median survival time of 20.6 months.Conclusion: This case series may contribute to the literature on thepathological and clinical aspects of the mixed adenoneuroendocrinecarcinoma of the gastrointestinal system.
🔖
Cite This Article
ULAŞ, M., BOSTANCI, E. B., ARAS, O., DÜZKÖYLÜ, Y. (2022). Mixed Adeno-Neuroendocrine Carcinoma; Case Series of Ten Patients with Review of the Literature. Balkan Medical Journal, Cilt: 35 - Sayı: 3, 263–267. https://ajindex.com/articles/460568
Volante M, Rindi G, Papotti M. The grey zone between pure (neuro) endocrine and non- (neuro) endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Wirchows Arch 2006;449:499-506.
Veits L, Lang-Schwarz C, Volkholz H, Falkeis C, Vieth M, Schulz H. Mixed adenoneuroendocrine carcinoma (MANEC) of the esophagogastric junction predominantly consisting of poorly differentiated neuroendocrine carcinoma. Endoscopy 2013;45(Suppl 2):16-7.
Juanmartinena JF, Fernandez-Urien I, Cordoba A, Miranda C, Borda A. Mixed adenoneuroendocrine carcinoma (MANEC) of the gastroesophageal junction: a case report and review of the literature. Rev Esp Enferm Dig 2017;109:160-2.
La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed aenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assesment of methylation profile, and search for prognostic markers. Am J Surg Pathol 2012;36:601-11.
Murata M, Takahashi H, Yamada M, Song M, Hiratsuka M. A case of mixed adenoneuroendocrine carcinoma of the pancreas. Immunohistochemical analysis for histogenesis. Medicine (Baltimore) 2017;96:e6225. Song W, Chen W, Zhang S, Peng J, He Y. Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy. Diagn Pathol 2012;7:163. Brathwaite S, Rock J, Yearsley MM, Bekaii-Saab T, Wei L, Frankel WL, et al. Mixed adeno-neuroendocrine carcinoma: an aggressive clinical entity. Ann Surg Oncol 2016;23:2281-6.
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
Chen MH, Kuo YJ, Yeh YC, Lin YC, Tzeng CH, Liu CY, et al. High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. J Chin Med Assoc 2015;78:454-9.
Acosta AM, Wiley EL. Primary biliary mixed adenoneuroendocrine carcinoma (MANEC). A short review. Arch Pathol Lab Med 2016;140:1157-62.
Mahansaria SS, Agrawal N, Arora A, Bihari C, Appukuttan M, Chattopadhyay TK. Ampullary mixed adenoneuroendocrine carcinoma: surprise histology, familiar management. Int J Surg Pathol 2017;7:585-91.
Solcia E, Klöppel G, Sobin LH. Histopathological Typing of Endocrine Tumours. 2nd ed. Berlin, Germany: Springer; 2000.
Acosta AM, Hamedani FS, Kajdacsy-Balla A, Wiley EL. Primary Mixed Adenoneuroendocrine Carcinoma of the Gallbladder in a 55-Year-Old Female Patient: A Case Report and